{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:51:49Z","timestamp":1781887909546,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,19]]},"DOI":"10.7759\/cureus.111154","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:00:08Z","timestamp":1781884808000},"source":"Crossref","is-referenced-by-count":0,"title":["Treatment Effect of Beta-Blocker Therapy After Acute Myocardial Infarction With Preserved or Mildly Reduced Ejection Fraction: A Systematic Review and Trial Sequential Analysis"],"prefix":"10.7759","author":[{"given":"Christopher","family":"Chinnatambi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Sakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul-Rahaman Adedolapo","family":"Ottun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prince K","family":"Darko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baffour","family":"Otchere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brice","family":"Njobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohene","family":"Poku Agyemang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Kanjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sammudeen","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"The G\u00f6teborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction","volume":"67","author":"Hjalmarson A","year":"1983","unstructured":"Hjalmarson A, Herlitz J, Holmberg S, et al.. The G\u00f6teborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation. 1983, 67:I26-32.","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198104023041401","article-title":"Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction","volume":"304","author":"The Norwegian Multicenter Study Group","year":"1981","unstructured":"The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981, 304:801-7. 10.1056\/NEJM198104023041401","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1983.03340200048027","article-title":"A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results","volume":"250","year":"1983","unstructured":"A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA. 1983, 250.2814-9. 10.1001\/jama.1983.03340200048027","journal-title":"JAMA"},{"key":"ref4","article-title":"Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group","volume":"2","year":"1986","unstructured":"Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction. ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet. 1986, 2:57-66.","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1982.03320370021023","article-title":"A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results","volume":"247","year":"1982","unstructured":"A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982, 247.1707-14. 10.1001\/jama.1982.03320370021023","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012565.pub2","article-title":"Beta-blockers in patients without heart failure after myocardial infarction","volume":"11","author":"Safi S","year":"2021","unstructured":"Safi S, Sethi NJ, Korang SK, Nielsen EE, Feinberg J, Gluud C, Jakobsen JC. Beta-blockers in patients without heart failure after myocardial infarction. Cochrane Database Syst Rev. 2021, 11:CD012565. 10.1002\/14651858.CD012565.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne RA","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, et al.. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023, 44:3720-826. 10.1093\/eurheartj\/ehad191","journal-title":"Eur Heart J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"85","author":"Rao SV","year":"2025","unstructured":"Rao SV, O'Donoghue ML, Ruel M, et al.. 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025, 85:2135-237. 10.1016\/j.jacc.2024.11.009","journal-title":"J Am Coll Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2110","article-title":"Long-term beta-blocker therapy after myocardial infarction in the reperfusion era: a systematic review","volume":"38","author":"Hong J","year":"2018","unstructured":"Hong J, Barry AR. Long-term beta-blocker therapy after myocardial infarction in the reperfusion era: a systematic review. Pharmacotherapy. 2018, 38:546-54. 10.1002\/phar.2110","journal-title":"Pharmacotherapy"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001221","article-title":"Long-term beta-blocker therapy after myocardial infarction without heart failure in the reperfusion era-systemic review and meta-analysis","volume":"79","author":"Kim Y","year":"2022","unstructured":"Kim Y, Byun S, Kim HY, Kim DB. Long-term beta-blocker therapy after myocardial infarction without heart failure in the reperfusion era-systemic review and meta-analysis. J Cardiovasc Pharmacol. 2022, 79:650-4. 10.1097\/FJC.0000000000001221","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvaa029","article-title":"Effect of beta-blocker therapy in patients with or without left ventricular systolic dysfunction after acute myocardial infarction","volume":"7","author":"Joo SJ","year":"2021","unstructured":"Joo SJ, Kim SY, Choi JH, et al.. Effect of beta-blocker therapy in patients with or without left ventricular systolic dysfunction after acute myocardial infarction. Eur Heart J Cardiovasc Pharmacother. 2021, 7:475-82. 10.1093\/ehjcvp\/pvaa029","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"Dargie HJ","year":"2001","unstructured":"Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet Lond Engl. 2001, 357:1385-90. 10.1016\/s0140-6736(00)04560-8","journal-title":"Lancet Lond Engl"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.12559","article-title":"\u03b2-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease","volume":"308","author":"Bangalore S","year":"2012","unstructured":"Bangalore S, Steg G, Deedwania P, et al.. \u03b2-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012, 308:1340-9. 10.1001\/jama.2012.12559","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.05.032","article-title":"Clinical outcomes with \u03b2-blockers for myocardial infarction: a meta-analysis of randomized trials","volume":"127","author":"Bangalore S","year":"2014","unstructured":"Bangalore S, Makani H, Radford M, et al.. Clinical outcomes with \u03b2-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med. 2014, 127:939-53. 10.1016\/j.amjmed.2014.05.032","journal-title":"Am J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401479","article-title":"Beta-blockers after myocardial infarction and preserved ejection fraction","volume":"390","author":"Yndigegn T","year":"2024","unstructured":"Yndigegn T, Lindahl B, Mars K, et al.. Beta-blockers after myocardial infarction and preserved ejection fraction. N Engl J Med. 2024, 390:1372-81. 10.1056\/NEJMoa2401479","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2504735","article-title":"Beta-blockers after myocardial infarction and preserved ejection fraction","volume":"393","author":"Ibanez B","year":"2025","unstructured":"Ibanez B, Latini R, Rossello X, et al.. Beta-blockers after myocardial infarction and preserved ejection fraction. N Engl J Med. 2025, 393:1889-900. 10.1056\/NEJMoa2504735","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505985","article-title":"Beta-blockers after myocardial infarction in patients without heart failure","volume":"393","author":"Munkhaugen J","year":"2025","unstructured":"Munkhaugen J, Kristensen AM, Halvorsen S, et al.. Beta-blockers after myocardial infarction in patients without heart failure. N Engl J Med. 2025, 393:1901-11. 10.1056\/NEJMoa2505985","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1017\/s0266462300102181","article-title":"A study of the references used in Cochrane protocols and reviews. Three bibles, three dictionaries, and nearly 25,000 other things","volume":"16","author":"Clarke M","year":"2000","unstructured":"Clarke M, Clarke T. A study of the references used in Cochrane protocols and reviews. Three bibles, three dictionaries, and nearly 25,000 other things. Int J Technol Assess Health Care. 2000, 16:907-9. 10.1017\/s0266462300102181","journal-title":"Int J Technol Assess Health Care"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-018-0699-4","article-title":"Registration of systematic reviews in PROSPERO: 30,000 records and counting","volume":"7","author":"Page MJ","year":"2018","unstructured":"Page MJ, Shamseer L, Tricco AC. Registration of systematic reviews in PROSPERO: 30,000 records and counting. Syst Rev. 2018, 7:32. 10.1186\/s13643-018-0699-4","journal-title":"Syst Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2512686","article-title":"Beta-blockers after myocardial infarction with normal ejection fraction","volume":"394","author":"Kristensen AM","year":"2026","unstructured":"Kristensen AM, Rossello X, Atar D, et al.. Beta-blockers after myocardial infarction with normal ejection fraction. N Engl J Med. 2026, 394:540-50. 10.1056\/NEJMoa2512686","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-074495","article-title":"A guide and pragmatic considerations for applying GRADE to network meta-analysis","volume":"381","author":"Izcovich A","year":"2023","unstructured":"Izcovich A, Chu DK, Mustafa RA, Guyatt G, Brignardello-Petersen R. A guide and pragmatic considerations for applying GRADE to network meta-analysis. BMJ. 2023, 381:e074495. 10.1136\/bmj-2022-074495","journal-title":"BMJ"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins JP","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002, 21:1539-58. 10.1002\/sim.1186","journal-title":"Stat Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.11","article-title":"Outlier and influence diagnostics for meta-analysis","volume":"1","author":"Viechtbauer W","year":"2010","unstructured":"Viechtbauer W, Cheung MW. Outlier and influence diagnostics for meta-analysis. Res Synth Methods. 2010, 1:112-25. 10.1002\/jrsm.11","journal-title":"Res Synth Methods"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian R","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986, 7:177-88. 10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1177\/0962280215583568","article-title":"Random-effects meta-analysis: the number of studies matters","volume":"26","author":"Guolo A","year":"2017","unstructured":"Guolo A, Varin C. Random-effects meta-analysis: the number of studies matters. Stat Methods Med Res. 2017, 26:1500-18. 10.1177\/0962280215583568","journal-title":"Stat Methods Med Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-018-0618-3","article-title":"Likelihood-based random-effects meta-analysis with few studies: empirical and simulation studies","volume":"19","author":"Seide SE","year":"2019","unstructured":"Seide SE, R\u00f6ver C, Friede T. Likelihood-based random-effects meta-analysis with few studies: empirical and simulation studies. BMC Med Res Methodol. 2019, 19:16. 10.1186\/s12874-018-0618-3","journal-title":"BMC Med Res Methodol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.06.024","article-title":"Primary and secondary outcome reporting in randomized trials: JACC State-of-the-Art Review","volume":"78","author":"Pocock SJ","year":"2021","unstructured":"Pocock SJ, Rossello X, Owen R, Collier TJ, Stone GW, Rockhold FW. Primary and secondary outcome reporting in randomized trials: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021, 78:827-39. 10.1016\/j.jacc.2021.06.024","journal-title":"J Am Coll Cardiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/pst.1919","article-title":"Subgroup analysis and interpretation for phase 3 confirmatory trials: white paper of the EFSPI\/PSI working group on subgroup analysis","volume":"18","author":"Dane A","year":"2019","unstructured":"Dane A, Spencer A, Rosenkranz G, Lipkovich I, Parke T. Subgroup analysis and interpretation for phase 3 confirmatory trials: white paper of the EFSPI\/PSI working group on subgroup analysis. Pharm Stat. 2019, 18:126-39. 10.1002\/pst.1919","journal-title":"Pharm Stat"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c117","article-title":"Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses","volume":"340","author":"Sun X","year":"2010","unstructured":"Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ. 2010, 340:c117. 10.1136\/bmj.c117","journal-title":"BMJ"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev J","year":"2008","unstructured":"Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008, 61:64-75. 10.1016\/j.jclinepi.2007.03.013","journal-title":"J Clin Epidemiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in random-effects model meta-analyses","volume":"9","author":"Wetterslev J","year":"2009","unstructured":"Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol. 2009, 9:86. 10.1186\/1471-2288-9-86","journal-title":"BMC Med Res Methodol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404204","article-title":"Beta-blocker interruption or continuation after myocardial infarction","volume":"391","author":"Silvain J","year":"2024","unstructured":"Silvain J, Cayla G, Ferrari E, et al.. Beta-blocker interruption or continuation after myocardial infarction. N Engl J Med. 2024, 391:1277-86. 10.1056\/NEJMoa2404204","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199347","article-title":"Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention","volume":"13","author":"Watanabe H","year":"2018","unstructured":"Watanabe H, Ozasa N, Morimoto T, et al.. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PLoS One. 2018, 13:e0199347. 10.1371\/journal.pone.0199347","journal-title":"PLoS One"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.03.578","article-title":"\u0392-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction","volume":"69","author":"Dondo TB","year":"2017","unstructured":"Dondo TB, Hall M, West RM, et al.. \u0392-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction. J Am Coll Cardiol. 2017, 69:2710-20. 10.1016\/j.jacc.2017.03.578","journal-title":"J Am Coll Cardiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.120.010159","article-title":"Left ventricular ejection fraction 1 year after acute myocardial infarction identifies the benefits of the long-term use of \u03b2-blockers: analysis of data from the KAMIR-NIH Registry","volume":"14","author":"Park CS","year":"2021","unstructured":"Park CS, Yang HM, Ki YJ, et al.. Left ventricular ejection fraction 1 year after acute myocardial infarction identifies the benefits of the long-term use of \u03b2-blockers: analysis of data from the KAMIR-NIH Registry. Circ Cardiovasc Interv. 2021, 14:e010159. 10.1161\/CIRCINTERVENTIONS.120.010159","journal-title":"Circ Cardiovasc Interv"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland JG","year":"2018","unstructured":"Cleland JG, Bunting KV, Flather MD, et al.. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018, 39:26-35. 10.1093\/eurheartj\/ehx564","journal-title":"Eur Heart J"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2023.03.017","article-title":"Beta-blocker use and heart failure outcomes in mildly reduced and preserved ejection fraction","volume":"11","author":"Arnold SV","year":"2023","unstructured":"Arnold SV, Silverman DN, Gosch K, et al.. Beta-blocker use and heart failure outcomes in mildly reduced and preserved ejection fraction. JACC Heart Fail. 2023, 11:893-900. 10.1016\/j.jchf.2023.03.017","journal-title":"JACC Heart Fail"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01592-2","article-title":"\u03b2 blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials","volume":"406","author":"Rossello X","year":"2025","unstructured":"Rossello X, Prescott EIB, Kristensen AMD, et al.. \u03b2 blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials. Lancet Lond Engl. 2025, 406:1128-37. 10.1016\/S0140-6736(25)01592-2","journal-title":"Lancet Lond Engl"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.02.057","article-title":"Meta-analysis of relation between oral \u03b2-blocker therapy and outcomes in patients with acute myocardial infarction who underwent percutaneous coronary intervention","volume":"115","author":"Huang BT","year":"2015","unstructured":"Huang BT, Huang FY, Zuo ZL, et al.. Meta-analysis of relation between oral \u03b2-blocker therapy and outcomes in patients with acute myocardial infarction who underwent percutaneous coronary intervention. Am J Cardiol. 2015, 115:1529-38. 10.1016\/j.amjcard.2015.02.057","journal-title":"Am J Cardiol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwae298","article-title":"Beta-blockers for secondary prevention following myocardial infarction in patients without reduced ejection fraction or heart failure: an updated meta-analysis","volume":"32","author":"Chi KY","year":"2025","unstructured":"Chi KY, Lee PL, Chowdhury I, et al.. Beta-blockers for secondary prevention following myocardial infarction in patients without reduced ejection fraction or heart failure: an updated meta-analysis. Eur J Prev Cardiol. 2025, 32:633-46. 10.1093\/eurjpc\/zwae298","journal-title":"Eur J Prev Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/479682-treatment-effect-of-beta-blocker-therapy-after-acute-myocardial-infarction-with-preserved-or-mildly-reduced-ejection-fraction-a-systematic-review-and-trial-sequential-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:00:09Z","timestamp":1781884809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/479682-treatment-effect-of-beta-blocker-therapy-after-acute-myocardial-infarction-with-preserved-or-mildly-reduced-ejection-fraction-a-systematic-review-and-trial-sequential-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":42,"URL":"https:\/\/doi.org\/10.7759\/cureus.111154","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,19]]}}}